LOS ANGELES--(BUSINESS WIRE)--Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Cleveland BioLabs, Inc. (“Cleveland BioLabs” or the “Company”) (NASDAQ: CBLI) concerning possible violations of federal securities laws. The investigation is focused on certain statements issued by Cleveland BioLabs concerning the Company’s business and financial prospects.
Please contact us at (212) 682-5340, Toll-Free at (888) 773-9224, or at shareholders@glancylaw.com to discuss this matter. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
Cleveland BioLabs is a clinical-stage biotechnology company, engaged in the research, development and commercialization of products that have the potential to treat cancer, reduce death from total body irradiation and counteract the genotoxic effects of radio and chemotherapies for oncology patients. The investigation focuses on certain statements contained in the Registration Statement issued in connection with the Company’s January 14, 2014, public securities offering, related to funding from the Biomedical Advanced Research Development Authority.
On January 23, 2014, shortly after the offering, Cleveland BioLabs announced that the Biomedical Advanced Research Development Authority “terminated negotiations related to the company’s proposal for further development of Entolimod as a medical radiation countermeasure.”
If you purchased Cleveland BioLabs securities pursuant to the January 14, 2014, public offering, if you have information or would like to learn more about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at (888) 773-9224, or contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
